Shenzhen Zhuoqiao Medical Immunology Technology Co., Ltd. is a brand under the umbrella of Shenzhen Zhuoqiao Medical Immunology Technology Co., Ltd. Established in 2025, it is composed of several frontline R&D personnel with over ten years of experience in the CGT drug industry. There are two main businesses: (1) research and development of high-throughput flow electric conversion equipment; (2) Serving hospitals and enterprises, we can provide mature and clinically applicable next-generation CGT cell drug preparation solutions.  

    The core technology mainly relies on gene delivery technology and iterative upgrading of equipment to achieve rapid preparation of immune cell drugs such as CAR-T, and to facilitate large-scale production of cell drugs. Addressing the issues of high prices and poor accessibility of cell drugs, and promoting the widespread clinical application of CAR-T and other cell drugs.  

    We have a mature solution for the preparation of non viral CGT cell drugs, based on cell electroporation technology, and have developed single stranded DNA production technology to replace traditional lentiviruses. The insertion efficiency of CAR remains stable at over 50%. Strong scalability, stable process and good reproducibility, capable of producing over 10000 CAR-T or TCR-T cell preparations annually.